Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease
Section snippets
Study population
Between February 1990 and October 1992, 15,502 patients with coronary artery disease, aged 45 to 74 years, from 18 cardiology departments throughout Israel, were screened for participation in a randomized placebo-controlled, secondary prevention trial—The Bezafibrate Infarction Prevention (BIP) study. Of these patients, 3,122 fulfilled the inclusion criteria (included group) and took part in the trial,7 which was aimed at evaluating the effectiveness of a lipid-modifying drug, bezafibrate, in
Baseline and clinical characteristics
During the follow-up period, 1,839 subjects died. We analyzed the cohort according to 3 groups: survivors (n = 12,858), CM (n = 1,055), and NCM (n = 626). A separate group of 158 deaths (8.6%) was excluded from the analysis due to death from unknown causes. Mean follow-up for the CM group was 2.7 ± 1.7 years, for the NCM group, mean follow-up was 3.2 ± 1.7 years, and for the 12,858 survivors, mean follow-up was 5.5 ± 0.8 years.
Among the patients who died, 269 participated in the BIP study (n =
Discussion
Over the mean 5.15-year follow-up period of this cohort, 1,839 coronary patients died. This represents a death rate of 2,275/100,000/year, which is 2.2 times higher than the mortality rate of Israelis aged 44 to 74 years in 1994 (the mid follow-up year of the study), which was 1,104/100,000/year.12 Because survival of patients with coronary heart disease following acute myocardial infarction has improved, these patients are increasingly exposed to other causes of death. Life expectancy at birth
References (30)
- et al.
Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarctionthe Framingham Study
Am Heart J
(1993) - et al.
Lung cancer mortality after 16 years in MRFIT participants in intervention and usual-care groups. Multiple Risk Factor Intervention Trial
Ann Epidemiol
(1997) - et al.
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patient with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention trial)
Am J Cardiol
(1993) - Braun AO, ed. Health in Israel. ICDC—Ministry of Health. Publication 202,...
- et al.
Improvement in the prognosis of patients with acute myocardial infarction in the 1990s compared with the prethrombolytic eraan analysis by age subgroups
Am J Geriatric Cardiol
(1995) Long-term effects of intravenous thrombolysis in acute myocardial infarctionFinal report of the GISSI study
Lancet
(1987)- et al.
Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group
Arch Intern Med
(1992) - National Center for Health Statistics. International Classification of Diseases. 9th Ed. Washington, DC: Government...
- SAS Institute Inc. SAS/STAT Software. User’s Guide Version 6. 4th Ed. Vols. I, II. Cary, NC: SAS Institute Inc.,...
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study
Circulation
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
J Am Coll Cardiol
Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey
BMJ
Report of the conference on low blood cholesterolmortality associations
Circulation
Cited by (37)
Causes and Predictors of Death in Patients With Coronary Heart Disease (from the Heart and Soul Study)
2017, American Journal of CardiologyRisk factors for mortality in patients with chronic obstructive pulmonary disease
2015, Atencion PrimariaClinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: Results from a multicenter atrial fibrillation registry study
2014, Journal of the American Medical Directors AssociationPrediction of Cardiovascular Disease: Framingham Risk Estimation and Beyond
2011, Preventive Cardiology: Companion to Braunwald's Heart Disease Expert Consult - Online and PrintLate-life dementia predicts mortality beyond established midlife risk factors
2011, American Journal of Geriatric PsychiatryCitation Excerpt :The inconsistency of these reported relationships suggests that it would be simplistic to interpret both dementia and cardiovascular risk factors as markers of a single underlying process affecting mortality. Consistent with other studies of both midlife and proximal predictors of late-life mortality, SES,26,27,50 systolic and diastolic blood pressure,29,31 and smoking28 were associated with mortality at that age range. Midlife total cholesterol was not associated with mortality, consistent with some studies51 but not with others.30
Precipitating factors of mortality in chronic obstructive pulmonary disease patients with frequent exacerbations
2010, Revista Clinica Espanola